CMS announces $50 monthly GLP-1 coverage for Medicare Part D beneficiaries
Medicare's new Bridge program caps the monthly copay at $50 for some GLP-1 weight-loss drugs, though the payment will not count toward Part D deductibles or the annual out-of-pocket cap.
Eligible Medicare Part D beneficiaries will be able to get certain GLP-1 medicines for a $50 monthly copay beginning July 1, 2026, the Centers for Medicare & Medicaid Services announced on May 6, 2026 [1]. The program, called the Medicare GLP-1 Bridge, runs through December 31, 2027 [1][2]. Medicare has long been barred from covering weight loss treatments, and the pilot marks a notable change [3].
CMS is offering the $50 copay for the pill and injectable formulations of Wegovy (semaglutide), the KwikPen formulation of Zepbound (tirzepatide), and the Foundayo (orforglipron) pill, all approved for weight loss [3].
To qualify, a person must be enrolled in a Medicare Part D plan and meet criteria based mainly on body weight and health status. People qualify with a body mass index of 27 or higher plus a condition such as heart disease or prediabetes, among others. People with a BMI of 35 or higher qualify automatically, according to NPR [3]. About 40% of American adults have a BMI of 30 or higher, which the Centers for Disease Control and Prevention classifies as obesity [3].
The Bridge is not a standard Part D benefit. It operates outside the Part D benefit's coverage and payment flow, so Part D sponsors do not carry risk for the drugs and do not have to opt in for beneficiaries to use the program [2]. In 2026, CMS will use a single central processor to manage prior authorization, claims adjudication and payment to pharmacies [2].
Patients need prior authorization. A doctor sends the prescription to a central system run by CMS contractor Humana, using a system already in place for another Medicare drug program, and doctors do not need to be enrolled as Medicare providers to write a prescription or submit a request. Once approved, patients pay the flat $50 copayment at the pharmacy [3].
The $50 does not count toward the Part D deductible or the $2,100 annual cap on out-of-pocket prescription drug costs, and the low-income subsidy is not available for these drugs under the Bridge [2][3].
Without insurance coverage, cash prices for these drugs typically range from $149 to $699 per month even with discounts, according to NPR [3]. On the government's TrumpRx discount site, Wegovy injectables run from $199 for a lower dose during the first two months to $399 for a higher dose, and the Zepbound KwikPen costs up to $699 per month. At the highest doses, the daily Wegovy pill costs up to $299 and Foundayo tops out at $349 [3].
"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," CMS Administrator Dr. Mehmet Oz said. "The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible" [1]. Chris Klomp, director of Medicare and chief counselor at the U.S. Department of Health and Human Services, said the demonstration is meant to make access "simpler, more predictable, and more consistent across the Medicare program" [1].
Why it matters for patients
The program changes what many Medicare beneficiaries would pay out of pocket. CMS has not published projections for how many people will enroll, and a previous KFF analysis estimated that close to 14 million Medicare beneficiaries were overweight or obese as of 2020 [3].
Cost remains an issue for some. About half of GLP-1 users say the drugs were difficult to afford, and a quarter said they were "very difficult," according to KFF polling [3]. People who receive the low-income subsidy, known as Extra Help, cannot use that assistance for drugs covered by the Bridge. "Fifty dollars a month sounds like a great deal compared to paying the discounted prices," said Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF, "but it's a lot of money for somebody who's living on a $750-a-month Social Security check" [3].
The $50 copay applies only when a GLP-1 is prescribed for weight loss. People already taking one of these drugs for a qualifying condition such as Type 2 diabetes, cardiovascular disease risk reduction or sleep apnea continue to get it through their regular Part D plan at that plan's price, which may be higher than $50 [3]. People already taking a GLP-1 for weight loss may qualify for the Bridge if their prescriber attests that they met the clinical criteria when they started the medication [3].
The program is temporary. Most studies show many people who stop taking GLP-1 drugs regain the weight they lost [3]. Cubanski said the extension will be "really expensive" for Medicare, adding that the cost is "likely to be billions of dollars a year in additional spending." CMS has not disclosed its own cost projections [3].
What happens next
The Bridge opens July 1, 2026, and ends December 31, 2027 [1][2]. It was initially planned to last six months, but CMS extended it to 18 months after not enough insurers signed on by an April deadline to a voluntary longer-term program. The BALANCE model is not launching in 2027, and CMS says the extension lets it collect more data on GLP-1 use to share with Part D plan sponsors [2][3].
CMS says it will share additional information for beneficiaries as the program begins, and that it is working with providers, pharmacies and manufacturers on implementation [1]. People with Medicare can check whether they may qualify at Medicare.gov/glp1bridge or call 1-800-MEDICARE (1-800-633-4227); TTY users can call 1-877-486-2048 [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.